Katherine Stueland was appointed President and CEO of GeneDx in 2021. In her more than two decade career in the healthcare sector, she has overseen multiple commercial organizations and corporate brand transformations, and helped bring the first cancer immunotherapy to market, enabling a new standard of care for patients.
Katherine is passionate about how genomics can improve health outcomes and is committed to ensuring GeneDx delivers it to anyone who could benefit. Additionally, she cares deeply about the importance of broadening research to diverse patient populations in an effort to advance science and patient care for all. “Right now, there is so much opportunity for us to make significant improvements in healthcare, and we at GeneDx have the best technology to do it,” she said.
For Katherine, what makes GeneDx special is not just the science, but also the relentless passion the GeneDx team has for delivering its services to patients. “Bringing the team together to figure out how we affect change for patients is the most exhilarating part of the job,” she explained. “The underlying technology and the team’s vision has the possibility of helping so many more people around the world.”
Prior to working for GeneDx, Katherine was the Chief Commercial Officer of Invitae Corporation, where she established the corporate brand as the company evolved from a private to a public entity with a market capitalization exceeding $6 billion. Before that, Katherine served as vice president of communications and investor relations at Dendreon, the first company to bring an immuno-oncology product to market. Katherine holds a Bachelor of Science in English Language and Literature from Miami University in Ohio.
Jennifer Brendel is a commercial leader with more than 20 years of experience building and growing brands that have had an impact on patients’ lives in addition to nurturing and leading teams who deliver high-impact, customer-centered and measurable initiatives. She’s had the privilege to work across a variety of commercial functions in many aspects of life sciences: pharmaceutical, over-the-counter, device and diagnostic on U.S., Regional (EU based in the UK) and global teams.
Jennifer came to GeneDx from Invitae where as the Head of Marketing (US + International) she helped to deliver ~70% YoY volume growth through improved and insight driven customer messaging, promotion, targeting, experience enhancements and channel optimization. Before joining Invitae, Jennifer was a Vice President at Bayer Consumer Health, North America (N.A.) where she established and led a team to drive increased consumer engagement through modern and relevant approaches (digital marketing, content strategy) and was one of only five people who redesigned and rebuilt the N.A. operating model to return to growth.
Prior to Bayer, Jennifer spent a decade at Pfizer working on blockbuster brands, including Aricept and Celebrex, among others. There she was involved in commercial strategy, non-personal promotion, sales force support and execution, lifecycle management, alliance management, business development in EU and market development in support of Rx-to-OTC switch.
Early in her career, Jennifer worked at leading global marketing communications firms and was a field sales representative for Tap Pharmaceuticals.
Kevin Feeley has served as CFO of OPKO Health’s diagnostics division which includes BioReference Laboratories, Inc. and GeneDx since 2018, Vice President of Finance from August 2016 through 2017 responsible for overall management and oversight of all finance and accounting and transactional matters. Prior to joining BioReference, Kevin served at US Controller Reckitt Benckiser, a global consumer packaged goods company focused on health, hygiene and nutrition brands. Prior to that Mr. Feeley led SEC reporting at Bausch Health Companies, a public specialty pharmaceutical company. Kevin spent twelve years at KPMG LLP with a focus in the pharmaceutical industry, having served the Firm’s largest global public companies. He is a Certified Public Accountant and holds a B.B.A. in Accounting from James Madison University.
Richard is an accomplished senior-level human strategist and business leader who applies the power of outstanding collaboration and teaming to deliver value. He has over 26 years of experience within the human resource function across multiple industries, with proven abilities to create sound human strategies that translate into aligned execution and business results.
Richard joined GeneDx in July 2021 as Chief Human Strategy Officer. He is responsible for leading global strategy development and tactical execution within the human strategy | human resource function supporting the organization.
Prior to joining GeneDx, Richard held various global and U.S. focused human resource roles of increasing responsibilities and complexity with the most recent being Chief Human Strategy Officer for The Medicines Company and its investigational therapy inclisiran, a first-in-class siRNA to lower LDL cholesterol through twice a year dosing. Richard also spent time within the consumer package goods and financial industry with category leaders including Con Agra Foods and M&M Mars Inc. and Ameritrade Inc. now TD Ameritrade.
He consistently demonstrated outstanding results leading human strategy planning; supporting executive and Board of Directors compensation planning in multiple therapeutic areas, serving on senior business leadership teams in M&A, project management and providing strategic counsel to fellow C-suite executives, which included CEO, CFO and COO.
Richard holds a B.S. in Human Resource Management from Bellevue University and an MBA from the University of Nebraska along with multiple Human Resource certifications (PHR, SPHR, GPHR, Six Sigma Greenbelt).
Sean Hofherr, PhD, FACMG, joined GeneDx in January of 2017 as Chief Scientific Officer. In December of 2018, he took on the additional role of CLIA Laboratory Director and in 2020, he was promoted to Executive Vice President. What Sean loves most about working for GeneDx is having the opportunity to use genetics to answer questions for patients at a scale unseen anywhere else. “It is such a mission-driven organization, and everyone here genuinely cares about the patients and providing them with the most accurate, high-quality results possible,” he said.
For Sean, one of his most memorable moments was when the company was able to launch an extremely high-volume, high-quality COVID PCR lab during the height of the pandemic at a scale never seen before at GeneDx — despite being outside the company’s core business. “Getting to a stable, mature operation took a huge amount of effort from many different people,” he explained. “But it was absolutely amazing to see people step up to the challenge, many of whom will be the future leaders of this company.”
Previously, Sean was Director of Molecular Diagnostics; Director of Biochemical Genetics and Metabolism; and Director of Quality within the Division of Laboratory Medicine, at Children’s National Medical Center in Washington, DC.
Sean received his PhD in Molecular and Human Genetics from Baylor College of Medicine, while focusing on projects related to gene therapy for propionic acidemia. He is board certified in clinical molecular and clinical biochemical genetics through training at the Mayo Clinic.
Rachel Klein joined GeneDx in 2011, and is responsible for managing service initiatives; leading genetic counseling and customer service teams; and working with marketing, payer relations and revenue cycle management to leverage technology solutions to improve business processes and service operations.
What Rachel enjoys most about working for GeneDx is the ability to serve its clients and patients. “Genetics is complex – from the technical aspects of running a test, to delivering the results in a simple, clear, and sensitive manner. I love being part of that daily challenge,” she said. “More importantly, being a part of the process to help patients and caregivers during what is often their most difficult time motivates me to continually push myself to find solutions that increase our ability to touch more lives.”
It is not surprising that Rachel’s favorite quote is from American author, Mark Twain: “The two most important days in your life are the day you are born and the day you find out why.” This particular quote resonates with Rachel because, “. . . we’re here for a purpose and to make a difference. We all have special talents, skills and assets, and using those to help others can have an everlasting impact for everyone.”
Rachel is a licensed and board-certified genetic counselor, having obtained her Masters in Human Genetics from Sarah Lawrence College. Rachel served as the Past-President, President, President-Elect, and Member-at-Large for the Human Genetics Association of New Jersey, and was actively involved in obtaining licensure for genetic counseling in that state.
Rachel has published in a number of peer-reviewed journal articles and presented her research at several professional meetings. She enjoys the challenges of genetics as a rapidly evolving field, and speaking with clinicians about the advances in genetic technology and implementation of testing in a medically and ethically sound manner.
Paul Kruszka, MD, joined GeneDx in 2021. He is a board-certified clinical geneticist who uses genomic and precision medicine to enhance the delivery of healthcare to individuals with rare diseases. In fact, what interests Paul most is the idea that genetic technology can be used to have a beneficial impact on people’s lives. “There are still many challenges to implementing genomic medicine, and this is what continues to keep me motivated,” he said.
Prior to working at GeneDx, Paul spent a decade at the National Institutes of Health conducting genomic research and taking care of individuals with rare genetic diseases. He is credited with the clinical and molecular delineation of multiple novel genetic conditions.
After attending medical school at the University of Michigan, Paul completed a family medicine residency at the University of Virginia. He also completed a clinical genetics residency at the National Human Genome Research Institute at the National Institutes of Health.
One of Paul’s favorite quotes is from the 19th century British novelist and poet, George Eliot: “It is never too late to be what you might have been.” Paul uses this quote to encourage himself and others to pursue goals, regardless of age.
A lifelong believer in the power of a story, Julie McKeough has built her career helping brands craft stories that drive behavior change in healthcare. From some of the biggest brands in the world to small start-ups, Julie’s wide-ranging expertise spans the communications continuum, from corporate communications and investor relations to brand identity and marketing.
“It’s the stories behind the samples that motivate everyone at GeneDx. So many of our patients are children. It’s their parents that I think about,” said Julie. “Not knowing what’s wrong with your child or how to help is devastating. Every answer that helps move beyond figuring out what’s wrong into focusing on what’s next helps those parents feel less powerless. It’s deeply gratifying to be part of trying to make that happen for more people.”
Most recently, Julie served as the head of brand and communications for Invitae, a leader in medical genetics. During her time with Invitae, Julie drove external communications strategies that took the company from little-known to routinely topping media share of voice for the genetics industry. She was part of the team that changed the conversation about genetics and health, including efforts that helped drive broad awareness of the limitations of over-the-counter genetic screening and others that triggered policy changes to increase access to genetic testing for cancer patients.
Prior to her time with Invitae, Julie spent nearly two decades as a consultant for some of the world’s biggest healthcare companies, helping drive awareness of products in women’s health, HIV, autoimmune disease and many other clinical areas. On the corporate communications side, Julie’s experience includes work on more than 15 M&A transactions, executive communications, internal communications and corporate social responsibility efforts. Early in her career Julie honed her communications and business skills at public relations agencies Porter/Novelli, Golin and Edelman.
Julie lives outside of Chicago with her husband and two sons.
Kyle Retterer began working for GeneDx in 2010, starting as a Bioinformatics Engineer and quickly moving up to his current position as Senior Vice President and Chief Technology Officer. Trained in physics and bioinformatics, his career in genomics has focused on building the analytical infrastructure to support the growth and adoption of next-generation sequencing diagnostic testing for germline disorders, including more than 275,000 clinical exomes performed at GeneDx.
Kyle leads a diverse team of scientists and engineers focused on building and scaling genomic analysis, and leveraging massive genomic and phenomic data sets to drive diagnostic efficiency and discovery. His team continues to push the diagnostics field forward by developing platforms and techniques to deliver whole genome sequencing as the next generation standard of care.
What excites Kyle most about the field of genomics is how much we still do not know or understand about the genome. “My background is in physics, where we seek to understand the essential nature of the universe,” said Kyle. “Genomics is an extension of the question, ‘How does the most complex thing in the universe – life – work?’ That we’ve gone from single-gene sequencing at the beginning of GeneDx, in 2000, to whole genome sequencing today is an incredible pace of achievement. This is only the beginning of unlocking the power of genomic information.”
Kyle has published more than 50 peer-reviewed articles since 2015, with a special focus on collaborative disease gene discovery and novel analytical approaches to NGS data. He attended the University of Maryland, where he received a Bachelor of Science in Physics and a Master of Science in Biotechnology and Bioinformatics. He also attended the French Culinary Institute, where he trained as a professional bread baker. In addition, Kyle loves designing and building vacuum tube amplifiers.